Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NPS Pharmaceuticals names new chief medical officer
Dr Garceau replaces Alan Harris who is leaving NPS for personal reasons but remains as a scientific advisor to the company. Dr Garceau joins NPS from Sanofi-Aventis, where
Dr Garceau replaces Alan Harris who is leaving NPS for personal reasons but remains as a scientific advisor to the company. Dr Garceau joins NPS from Sanofi-Aventis, where
After successful completion of Phase I established initial Mitogard stability and drug safety for the new intrathecal route for cyclosporin, the amount of $894,000 for year two was
Under the terms of the agreement, Evotec will progress the programs up to preclinical development and Novartis will then have the responsibility for all clinical development activities, manufacture
New investor Essex Woodlands Health Ventures led the round, with participation from existing investors Burrill & Company, HealthCare Ventures, Johnson & Johnson Development, Morgenthaler Ventures, Novartis BioVentures and
Tibotec said that it has collaborated with Emcure because of the company’s strong reputation in India and extensive reach through its country-wide distribution network. The agreement will help
According to the company, the Amplatzer cardiac plug (ACP) provides an innovative, minimally invasive solution for closing cardiac structures not involving the septal wall. One such intended use
Mr Graham will be responsible for all finance and information services matters in North America, effective January 1, 2009. Mr Graham will be a member of the US
Under the terms of the agreement, Sigma-Aldrich will exclusively distribute research quantities of SouthWest NanoTechnologies’s (SWeNT) CG 100, SWeNT SG 65 and SWeNT SG 76 single-wall nanotubes globally
According to the company, the primary analysis comparing XP19986 to placebo did not reach statistical significance. However, pre-defined subgroup analyses showed statistically significant benefits of XP19986 on a
According to the company, HZT-501, a novel, proprietary fixed-dose combination product containing ibuprofen and famotidine, has demonstrated a statistically significant reduction in the incidence of non-steroidal anti-inflammatory drug